FDA priority review for nivolumab Home › Forums › Melanoma Diagnosis: Stage IV › FDA priority review for nivolumab This topic is empty. Viewing 2 posts - 1 through 2 (of 2 total) Author Posts September 27, 2014 at 2:45 am #22180 RJoeyBParticipant As expected, the FDA today committed to a six-month priority review with BMS for nivolumab (“Opdivo”), following a similar process as that done with Merck for pembrolizumab (“Keytruda”): http://www.reuters.com/article/2014/09/26/us-bristol-myers-fda-idUSKCN0HL2EH20140926” class=”bbcode_url”>http://www.reuters.com/article/2014/09/26/us-bristol-myers-fda-idUSKCN0HL2EH20140926 September 27, 2014 at 3:12 pm #65475 Catherine PooleKeymaster Thanks for posting. I think this will be a long time til approval unfortunately, also not finding many EAP sites. So access is slow for nivo sadly. Author Posts Viewing 2 posts - 1 through 2 (of 2 total) The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.